Lipid Nanoparticles

Lipid nanoparticle (LNP)-based delivery of pharmaceuticals holds much promise for novel gene therapies, oncology, and effective, rapid-response vaccines. Platform technologies that characterize and quantify LNP attributes across R&D, production and quality control will help realize that promise. Click here to read a SelectScience editorial article on the latest advancements and expert opinions on characterizing LNPs for drug delivery.

Wyatt’s suite of solutions for analyzing critical LNP quality attributes including:

Average size, polydispersity and detailed size distributions

Particle concentration

Size-based nucleic acid (NA) payload distribution

Charge via zeta potential

Stability under a variety of stressors

Many of these assays can be streamlined and automated for high throughput.

Light scattering techniques are simple to operate and enhance productivity, while directly accessing the core biophysical properties that define these CQAs. Continue reading to learn about Wyatt’s solutions to industry and regulatory needs for LNPs and other nanopharmaceuticals.